Investigating a new anti-cancer drug targeting the Golgi pathway
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent
This study is looking at a new cancer-fighting drug that targets a specific pathway often found in breast cancer cells, and it's designed to kill those cancer cells without harming healthy ones, which could lead to better treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10861742 on NIH RePORTER |
What this research studies
This research focuses on a novel anti-cancer agent that targets the Golgi GOLPH3 pathway, which is often over-expressed in various cancers, including breast cancer. The study aims to understand how this drug works by identifying its specific targets within cancer cells. By using advanced screening techniques, researchers have found a small molecule that can selectively kill cancer cells while sparing normal cells. This approach could lead to new treatment options that work alongside existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers that exhibit over-expression of the GOLPH3 pathway, such as breast, lung, colorectal, or prostate cancers.
Not a fit: Patients with cancers that do not involve the GOLPH3 pathway or those with advanced-stage cancers that have exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for cancer patients, potentially improving survival rates and reducing side effects.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be a viable and innovative strategy.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Field, Seth J — Case Western Reserve University
- Study coordinator: Field, Seth J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.